Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

Jeffrey T Blue

Yan Li

Pingyu Zhong

Feng Dong

Rose M Cubbon

Holly A Hammond

Jon H Condra

Ayesha Sitlani

Kevin Caili Wang

Shilpa Pandit

Laurence B Peterson

Joseph C Santoro

Denise K Nawrocki

Dana D Wood

Henryk Mach

Heidi Pixley

Sonia M Gregory

Peter Peizhi Luo

Lynne Isopi

Timothy McCabe

Peizhi (Peter) Luo

Laura Orsatti

Heidi Yoder

Erin J Green-Trexler

Michael S Ryan

Sherrie-Ann P Martin

Patrick L Ahl

Akhilesh Bhambhani

Morrisa C Jones

Justin Stanbro

Jayme L Cannon

Michael J Caulfield

The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.

Formulations of dengue virus vaccine compositions

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

1B20 PCSK9 antagonists

1D05 PCSK9 antagonists

The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of(1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F or 33F) conjugated to a carrier protein, preferably CRM. The immunogenic composition, preferably formulated as a vaccine on an aluminum -based adjuvant, provides broad coverage against pneumococcal disease, particularly in infants and young children.

15-valent pneumococcal polysaccharide-protein conjugate vaccine composition

Growing community of inventors

Telford, PA, United States of America

Jeffrey T Blue